Zacharos Ioannis D, Efstathiou Stamatis P, Petreli Elisa, Georgiou George, Tsioulos Dimitrios I, Mastorantonakis Stylianos E, Christakopoulou Ioulia, Roussou Paraskevi P
Haematology-Oncology Unit, Third University Department of Medicine, Sotiria Hospital, 152 Mesogion Avenue, Athens 11527, Greece.
Eur J Haematol. 2002 Oct;69(4):221-6. doi: 10.1034/j.1600-0609.2002.02771.x.
To assess the association of serum CA 125 in patients with non-Hodgkin's lymphoma (NHL) with prognostic parameters of the disease, response to treatment, and survival.
Sixty-eight patients [38 males, median age 56 (range 17-82) yr] with NHL were evaluated. CA 125 was measured by an enzyme immunoradiometric assay at diagnosis and at the end of first-line treatment.
Median overall CA 125 was 49 (1-963) U mL-1, whereas 49 patients had initially abnormal (>35 U mL) CA 125 levels. High CA 125 was found to correlate with failure of treatment (P = 0.001) and relapse (P = 0.01), and to be independently associated with bulky disease, effusions, LDH, and the International Prognostic Index (IPI) score (P<0.01 for each of these four variables). An initially abnormal CA 125 value was associated with poorer 5-yr survival [median survival of patients with CA 125>35 U mL-1 33 (18-72) months compared to 58 (20-77) months for those with CA 125 = 35 U mL-1, P = 0.012]. Moreover, CA 125>35 U mL-1 (among stage III/IV and LDH>460 mU mL-1) emerged as an independent predictor of death within 5 yr from diagnosis (Relative Risk (RR) 3.1, 95% CI 1.5-12.8, P = 0.02).
Measurement of serum CA 125 is useful for staging, monitoring, and estimating prognosis in patients with NHL.
评估非霍奇金淋巴瘤（NHL）患者血清CA 125与疾病预后参数、治疗反应及生存情况之间的关联。
对68例NHL患者[38例男性，中位年龄56岁（范围17 - 82岁）]进行评估。在诊断时及一线治疗结束时采用酶免疫放射分析法测定CA 125。
总体CA 125中位值为49（1 - 963）U/mL，49例患者初始CA 125水平异常（>35 U/mL）。发现高CA 125与治疗失败（P = 0.001）及复发（P = 0.01）相关，且与大包块病变、胸腔积液、乳酸脱氢酶（LDH）及国际预后指数（IPI）评分独立相关（这四个变量中的每一个P均<0.01）。初始CA 125值异常与较差的5年生存率相关[CA 125>35 U/mL的患者中位生存期为33（18 - 72）个月，而CA 125 = 35 U/mL的患者为58（20 - 77）个月，P = 0.012]。此外，CA 125>35 U/mL（在Ⅲ/Ⅳ期及LDH>460 mU/mL的患者中）成为诊断后5年内死亡的独立预测因素（相对风险（RR）3.1，95%置信区间1.5 - 12.8，P = 0.02）。
血清CA 125检测对NHL患者的分期、监测及预后评估有用。
Zotero 插件